Bolt Biotherapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
BOLT
- Investments
-
1
- Share Price
-
$4.96
- (As of Friday Closing)
Bolt Biotherapeutics General Information
Description
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Contact Information
Website
www.boltbio.comCorporate Office
- 900 Chesapeake Drive
- Redwood City, CA 94063
- United States
Corporate Office
- 900 Chesapeake Drive
- Redwood City, CA 94063
- United States
Bolt Biotherapeutics Stock Performance
As of 20-Nov-2026, Bolt Biotherapeutics’s stock price is $4.96. Its current market cap is $12.8M with 2.61M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.96 | $5.06 | $3.10 - $7.78 | $12.8M | 2.61M | 255K | -$13.93 |
Bolt Biotherapeutics Financials Summary
As of 30-Sep-2026, Bolt Biotherapeutics has a trailing 12-month revenue of $2.53M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,115 | 2,175 | (15,141) | (56,345) |
| Revenue | 2,531 | 7,695 | 7,690 | 7,876 |
| EBITDA | (26,451) | (34,572) | (66,573) | (74,296) |
| Net Income | (26,180) | (33,376) | (63,118) | (69,197) |
| Total Assets | 35,591 | 56,748 | 99,632 | 159,784 |
| Total Debt | 20,889 | 22,958 | 25,209 | 20,219 |
Bolt Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bolt Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Bolt Biotherapeutics Comparisons
Industry
Financing
Details
Bolt Biotherapeutics Competitors (43)
One of Bolt Biotherapeutics’s 43 competitors is Jasper Therapeutics, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Jasper Therapeutics | Formerly VC-backed | Redwood City, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada |
Bolt Biotherapeutics Patents
Bolt Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026055185-A1 | Sting agonist immunoconjugates and uses thereof | Pending | 04-Sep-2024 | ||
| WO-2026050214-A1 | Anti-claudin, tlr agonist immunoconjugates and uses thereof | Pending | 27-Aug-2024 | ||
| WO-2026050213-A8 | Tlr agonist immunoconjugates and uses thereof | Pending | 27-Aug-2024 | ||
| WO-2024216089-A1 | Anti-dectin-2 antibody combination therapy | Inactive | 13-Apr-2023 | ||
| WO-2024186626-A1 | Aza-bicyclic sting agonist immunoconjugates, and uses thereof | Inactive | 03-Mar-2023 | A61K47/6835 |
Bolt Biotherapeutics Signals
Bolt Biotherapeutics Acquisitions (1)
Bolt Biotherapeutics’s most recent deal was a Reverse Merger with Prana Therapies. The deal was made on 23-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Prana Therapies | 23-Oct-2026 | Reverse Merger | Drug Discovery |
Bolt Biotherapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Bolt Biotherapeutics FAQs
-
When was Bolt Biotherapeutics founded?
Bolt Biotherapeutics was founded in 2015.
-
Where is Bolt Biotherapeutics headquartered?
Bolt Biotherapeutics is headquartered in Redwood City, CA.
-
What is the size of Bolt Biotherapeutics?
Bolt Biotherapeutics has 23 total employees.
-
What industry is Bolt Biotherapeutics in?
Bolt Biotherapeutics’s primary industry is Drug Discovery.
-
Is Bolt Biotherapeutics a private or public company?
Bolt Biotherapeutics is a Public company.
-
What is Bolt Biotherapeutics’s stock symbol?
The ticker symbol for Bolt Biotherapeutics is BOLT.
-
What is the current stock price of Bolt Biotherapeutics?
As of 20-Nov-2026 the stock price of Bolt Biotherapeutics is $4.96.
-
What is the current market cap of Bolt Biotherapeutics?
The current market capitalization of Bolt Biotherapeutics is $12.8M.
-
What is Bolt Biotherapeutics’s current revenue?
The trailing twelve month revenue for Bolt Biotherapeutics is $2.53M.
-
Who are Bolt Biotherapeutics’s competitors?
Jasper Therapeutics, Adaptimmune Therapeutics, CytomX Therapeutics, Kite Pharma, and Zymeworks are some of the 43 competitors of Bolt Biotherapeutics.
-
What is Bolt Biotherapeutics’s annual earnings per share (EPS)?
Bolt Biotherapeutics’s EPS for 12 months was -$13.93.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process